GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Pharmaceutical Group Ltd (HKSE:03320) » Definitions » EV-to-Revenue

China Resources Pharmaceutical Group (HKSE:03320) EV-to-Revenue : 0.15 (As of May. 21, 2024)


View and export this data going back to 2016. Start your Free Trial

What is China Resources Pharmaceutical Group EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, China Resources Pharmaceutical Group's enterprise value is HK$40,951 Mil. China Resources Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$267,652 Mil. Therefore, China Resources Pharmaceutical Group's EV-to-Revenue for today is 0.15.

The historical rank and industry rank for China Resources Pharmaceutical Group's EV-to-Revenue or its related term are showing as below:

HKSE:03320' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.26   Med: 0.35   Max: 0.68
Current: 0.15

During the past 11 years, the highest EV-to-Revenue of China Resources Pharmaceutical Group was 0.68. The lowest was 0.26. And the median was 0.35.

HKSE:03320's EV-to-Revenue is ranked better than
97.46% of 1025 companies
in the Drug Manufacturers industry
Industry Median: 2.41 vs HKSE:03320: 0.15

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-21), China Resources Pharmaceutical Group's stock price is HK$6.00. China Resources Pharmaceutical Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$42.60. Therefore, China Resources Pharmaceutical Group's PS Ratio for today is 0.14.


China Resources Pharmaceutical Group EV-to-Revenue Historical Data

The historical data trend for China Resources Pharmaceutical Group's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Pharmaceutical Group EV-to-Revenue Chart

China Resources Pharmaceutical Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.28 0.28 0.33 0.32

China Resources Pharmaceutical Group Semi-Annual Data
Dec13 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 - 0.33 - 0.32

Competitive Comparison of China Resources Pharmaceutical Group's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Pharmaceutical Group's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Pharmaceutical Group's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Pharmaceutical Group's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where China Resources Pharmaceutical Group's EV-to-Revenue falls into.



China Resources Pharmaceutical Group EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

China Resources Pharmaceutical Group's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=40951.255/267652.155
=0.15

China Resources Pharmaceutical Group's current Enterprise Value is HK$40,951 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Resources Pharmaceutical Group's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$267,652 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Pharmaceutical Group  (HKSE:03320) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

China Resources Pharmaceutical Group's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=6.00/42.603
=0.14

China Resources Pharmaceutical Group's share price for today is HK$6.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$42.60.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Pharmaceutical Group EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of China Resources Pharmaceutical Group's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Pharmaceutical Group (HKSE:03320) Business Description

Traded in Other Exchanges
Address
26 Harbour Road, 41st Floor, China Resources Building, Room 4104-05, Wanchai, HKG
CR Pharma, is a vertically integrated conglomerate that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the third largest drug distributor by revenue, with a strong presence in Eastern, Northern, and Southern China. Its drug manufacturing segment primarily consists of four listed subsidiaries, Dong E E Jiao, CR Sanjiu, CR Double Crane, and Jiangzhong Pharmaceutical, which are well-known makers of over-the-counter traditional Chinese medicines (or TCM), health supplements, and prescription drugs. We estimate the company's operating income is approximately 53% distribution, 46% manufacturing, and less than 1% retail pharmacies.

China Resources Pharmaceutical Group (HKSE:03320) Headlines

No Headlines